| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 12
| Issue : 3 | Page : 96-99 |
|
|
Radiation therapy as an adjuvant treatment after breast-conserving surgery in ductal carcinoma In situ of the breast
Marwen Benna, Raouia Ben Amor, Zeineb Naimi, Meriem Bohli, Lotfi Kochbati
Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana; University of Tunis El Manar, Faculty of Medicine of Tunis, 1007, Tunisia
Correspondence Address:
Dr. Raouia Ben Amor
Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080, Ariana; University of Tunis El Manar, Faculty of Medicine of Tunis, 1007
Tunisia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrcr.jrcr_24_21
|
|
|
Ductal carcinoma in situ (DCIS) of the breast is a nonmalignant tumor of the breast with a rising incidence due to systematic mammographic screening. Actual consensus on conservative therapy is based on lumpectomy followed by adjuvant radiation therapy to the whole breast. This approach has been established after multiple large clinical trials and confirmed with subsequent meta-analyses. However, there are still debates on the benefit of adjuvant radiation therapy in a largely undefined “low-risk population.” This review tries to discuss actual data on this matter and discuss the benefits and risks of radiation therapy after lumpectomy in DCIS.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
